Antibody Dependent Cell-Mediated Cytotoxicity in Patients with Urologic Cancers: A Change by Surgical Operation, Histologic Grades and Clinical Stages / 대한비뇨기과학회지

ABSTRACT

In an attempt to evaluate the immune competence of urologic cancer patients, antibody-dependent cell-mediated cytotoxicity (ADCC) were performed in thirty-four patients and same numbers of age and sex matched normal controls. Also we compared of the level of ADCC before and after the operation. Concomittantly the values of ADCC were examined by histological grading and clinical staging. We used 51Cr-labelled chicken erythrocytes sensitized with 7s rabbit anti-chicken erythrocytes antibody as target cells and patient peripheral mononuclear cells as effector cells. 1. Effector cells of the patients with the urologic cancer showed significantly lower ADCC than those of normal controls. 1) All urologic cancer. Controls 41.4+/-6.0% (n=34) Preoperation 22.1+/-6.8% (n=34) 2) Transitional cell carcinoma of the renal pelvis and the bladder. Controls 41.7+/-6.1% (n=28) Preoperation 22.5+/-6.3% (n=28) 3)Non-transitional cell carcinoma(renal cell Ca. prostate ca. penis ca. seminoma). Controls 40.2+/-5.9% (n=6) Preoperation 20.6+/-4.6% (n=6) 2. In the patients with the transitional cell carcinoma of the bladder and the renal pelvis, highly graded patients had tendency to have lower response of ADCC. Grade I 27.3+/-4.0% (n=14) Grade II 19.9+/-4.l% (n=7) Grade III 15.5+/-3.2% (n=7) 3. In the patients with bladder carcinoma highly staged patients had tendency have lower response of ADDC. Stage T